Close to 50 genetic loci have been associated with type 2 diabetes (T2D), but they explain only 15% of the heritability. In an attempt to identify additional T2D genes, we analyzed global gene expression in human islets from 63 donors. Using 48 genes located near T2D risk variants, we identified gene coexpression and protein-protein interaction networks that were strongly associated with islet insulin secretion and HbA 1c . We integrated our data to form a rank list of putative T2D genes, of which CHL1, LRFN2, RASGRP1, and PPM1K were validated in INS-1 cells to influence insulin secretion, whereas GPR120 affected apoptosis in islets. Expression variation of the top 20 genes explained 24% of the variance in HbA 1c with no claim of the direction. The data present a global map of genes associated with islet dysfunction and demonstrate the value of systems genetics for the identification of genes potentially involved in T2D.
INTRODUCTION
Type 2 diabetes (T2D) is one of the fastest increasing diseases worldwide, with an estimated prevalence of 280 million affected patients in 2011 (http://www.diabetesatlas.org/). This epidemic has been ascribed to an interaction between common genetic variants and environmental factors like obesity and a sedentary lifestyle. To date, genome-wide association studies (GWAS) have identified 47 common genetic variants associated with T2D or glucose/insulin levels Saxena et al., 2007 Saxena et al., , 2010 ; Scott et Despite this apparent success, these variants explain only about 10%-15% of the heritability of T2D, emphasizing the need for novel approaches to identify susceptibility genes. One alternative strategy is to use genetic loci associated with expression traits in disease-relevant tissues to identify previously unrecognized susceptibility variants (Schadt et al., 2008) . Although T2D is characterized by both impaired insulin secretion and action in target tissues like muscle, fat, and liver (Defronzo, 2009) , most of the known disease-associated variants seem to influence insulin secretion rather than action (Florez, 2008; Ingelsson et al., 2010; Lyssenko et al., 2008) . In most cases the causal variant is not known, nor is it known how the identified variants may influence islet function in man. One of the obstacles in human diabetes research has been the inaccessibility of pancreatic islets. Recently, this hurdle has to some extent been circumvented by research using islets from cadaver donors intended for islet transplantation.
We have systematically characterized donated human islets by performing cDNA microarray and GWAS in addition to measuring insulin response to glucose and glycemic control (HbA 1c ) from the same individuals. Here, we have combined data from human islet gene expression, genetics, and function to build a global map of genes associated with islet dysfunction in T2D. We form a rank list of potential T2D genes, highlighting several candidate genes that might affect islet function in man.
RESULTS

Expression Pattern of 48 Putative T2D-Associated Genes in Human Islets
Using microarray data from human islets from 63 cadaver donors (nine with T2D), we studied the expression of 48 genes (47 SNPs) located in the vicinity of the known single-nucleotide polymorphisms (SNPs) that to date have been associated with T2D or glycemic traits (hereafter referred to as T2D seeder genes). The expression of IGF1, CHCHD9, PPARG, and HMGA2 did not differ significantly from background (after Bonferroni correction). Twenty-one genes starting from ARAP1 showed higher expression than the mean expression of all genes on the array (p < 0.05). The highest transcript levels were seen for G6PC2 and SLC30A8 ( Figure 1A ), whose expression was restricted to islets and absent in peripheral blood leukocytes ( Figure S1 ). At genome-wide level, 72 genes showed higher expression than SLC30A8 in pancreatic islets. We then studied transcript abundance in donors with known T2D or hyperglycemia (HbA 1c R 6%) compared with normoglycemic donors (no known T2D and HbA 1c < 6%) (Figures 1B and 1C) . The expression of KCNJ11, WFS1, SLCA2A, JAZF1, and G6PC2 was decreased in islets from T2D donors. Furthermore, increased expression of these genes in islets was associated with higher insulin secretion and lower HbA 1c ( Figures 1D-1I ).
cis and trans Effects of T2D-Associated SNPs on Gene Expression in Human Islets
The majority of known risk variants for T2D are located in intronic or intergenic regions, suggesting that they may influence gene expression. We therefore analyzed whether any of the 47 T2D-associated SNPs would influence gene expression in cis (within 1 Mb of the SNP) or in trans (further than 1 Mb away or on a different chromosome) by applying a linear model with additive effects. For cis eQTLs a significance threshold of p < 0.001 was defined based upon 1,000 permutations. For trans eQTLs with a very large number of tests (901,863), we applied a p value threshold of p < 0.00019 using the best p values of 1,500 random SNPs, referring to the 5% showing the strongest trans eQTLs. We observed 5 cis and 176 trans eQTLs ( Figure S2 and Table  S1 ). Of the trans eQTLs, the highest numbers were seen for the G6PC2 (rs560887) (n = 66) and the GCKR (rs780094) (n = 31) variants (Table S1 ). None of the five cis eQTLs showed different expression in islets from normo-and hyperglycemic donors. By slightly relaxing the p values for cis effects, we observed that risk T allele carriers of rs5912 in the KCJN11 gene were associated with decreased expression of KCJN11 (p = 0.005) in human islets. We also confirmed the previously shown elevated expression of the TCF7L2 gene in carriers of risk genotype (T) for rs7903146 (p = 0.02).
Pathways Based upon Coexpression Analysis with Putative T2D Associated Genes
Genes with similar expression patterns are hypothesized to share functional relationships and may represent pathways of interest for the pathogenesis of islet dysfunction in T2D (Inouye et al., 2010) . Thus, we correlated the expression of the 48 T2D seeder genes with the $20,000 genes on the array. Genes showing strong correlation with the T2D seeder genes were considered coexpressed (r s > 0.8 or < À0.8; genome-wide p = 4.73 3 10 À8 ). Of individual genes, SLC30A8, G6PC2, and GCK showed the largest number of coexpressed genes (130, 142, and 167) ( Figure 2A and Table S2 ), while for 26 genes expression did not correlate with any gene. By restricting the analysis to genes coexpressed with at least two of the 48 T2D seeder genes, we observed a strongly connected network of 248 genes (including 14 seeder genes), which we called T2DNet ( Figure 2B ). To investigate whether this network represented a relevant collection of T2D-associated genes in human islets, we analyzed coexpression of 48 randomly selected genes in a set of 10,000 randomly selected networks of the same size. As shown in Figure S3 , the T2DNet showed significantly more coexpressed genes than the randomly selected networks (p < 0.01). We next plotted the centroid (mean expression of the coregulated genes) of T2DNet gene expression against insulin secretion and HbA 1c levels ( Figure 2C ). The mean centroid showed a positive correlation with insulin release and an inverse correlation with HbA 1c . These correlations could not be reproduced in a set of 1,000 randomly selected gene networks of the same size. Also, the mean centroid of the T2DNet gene expression was markedly decreased in islets from T2D compared with nondiabetic donors ( Figure 2D ). Next, we restricted the network to genes that were coexpressed with at least four known T2D seeder genes. This generated a more condensed network (Figure 2E ), which we call T2DNet core. Of the 23 genes in this restricted network, 14 candidate genes for T2D were identified (KLHDC5, SNAP91, MAFB, PPM1K, RGAG4, SH3GL2, FAM46C, RPS6KA6, MAPRE3, CLCN4, NMNAT2, TMEM63C, ELAVL4, and NOL4) . Expression of these genes differed significantly between normoglycemic and hyperglycemic donors ( Figure 2F and Table S3 ). Furthermore, they correlated positively with insulin secretion and negatively with HbA 1c (Figures 2G and S3) (permuted 1,000 times by randomly selected lists of 14 genes at a p < 0.01). These 14 genes were included in the ranking of T2D-associated genes (see below). The mean centroid of the T2DNet core was significantly decreased in islets from diabetic versus nondiabetic donors ( Figure 2H ). Finally, we analyzed whether SNPs within a region spanning ± 50 kb up and downstream of 234 T2DNet genes (excluding the 14 seeder genes, in total 44,319 SNPs) were associated with T2D in the DIAGRAM+ database (Voight et al., 2010) (Table S4 ). These 12 genes were included in the ranking of T2D-associated genes (see below).
Molecular Interaction Networks
To obtain information on functional pathways that may characterize the T2DNet, we subdivided the network into modules using the EAGLE algorithm (Shen et al., 2009) . Four functional modules were identified. Module 1 consisted of WFS1, KCNJ11, GCK, and MADD, while module 2 included G6PC2, SLC30A8, FADS1, and SLC2A2. The other two modules were smaller; module 3 included IGFBP2 and JAZF1 and module 4 NOTCH2 and GCKR ( Figure 3A ). These modules were enriched for genes regulating b cell function (p = 1.4 3 10 À6 ) in the Reactome database (http://david.abcc.ncifcrf.gov/). To verify the functional connectivity of these modules, we interrogated the public STRING database compiling predicted proteinprotein interactions (PPI). T2DNet genes were found to interact with each other more often than expected by chance alone in the PPI database (p = 0.000012) ( Figure S5 ). Expansion of the four modules to the global PPI network indicated a 4-to 10-fold enrichment of T2D seeder genes (Table S5 ). In general, disease genes tend to be tissue-specific and functionally located in the periphery of the network (Barabá si et al., 2011), which was also seen here for the T2D seeder genes. In the PPI network, 2,607 genes were first-order neighbors of the T2DNet seeder genes. Using network topology to prioritize these 2,607 genes, we identified 162 genes showing significant connectivity within the PPI network (hypergeometric distribution p < 0.05). Of them, 142 genes had significant connection with only one T2D seeder gene, 11 with 2 genes, and 9 with R 3 genes. The nine genes showing connection with R 3 T2D genes (LGR5, PDX1, CDC123, NEUROD1, INS, FOXA2, ABCC8, PAX6, and GCG) were included in the ranking of T2D associated genes (see below). Of note, expression of PDX1, FOXA2, ABCC8, and PAX6 differed between islets from hyperglycemic and normoglycemic donors ( Figure 3B ) and correlated with insulin secretion and HbA 1c levels ( Figure S4 ).
Genes Differentially Expressed in Pancreatic Islets from Hyperglycemic and Normoglycemic Donors
Next we analyzed differential expression of genes in islets by stratifying the donors on T2D status or HbA 1c (normoglycemic < 6% and hyperglycemic R 6%). Using a cutoff of p < 0.001, we observed 118 genes that were differentially expressed in donors with known diabetes and 129 in hyperglycemic donors (Table S6 ). Of them, 18 genes were differentially expressed in both comparisons and were included in the subsequent ranking ( Figure 4A ). To exclude that these differences were due to differences in purity between diabetic and nondiabetic islets, we also adjusted the results for purity measured by dithizon and DNA content of the islets, but results remained virtually unchanged (data not shown). Those 18 genes included the receptors IL1R2, GLP1R, GPR120, BDKRB1, and the Wnt signaling regulator SFRP4. For GPR120, CHL1, GLP1R, and LRNF2, high expression in islets was associated with increased insulin (E) Illustration of T2DNet core in Cytoscape. T2DNet core was formed by restricting the coexpression analysis to at least four seeder genes of the 48 T2D with a cutoff value of r > 0.8 or < À0.8. We identified 14 genes whose expression was correlated to a cluster of 4-6 seeder T2D genes. Yellow nodes are the T2D genes and blue nodes are the identified 14 genes. secretion and lower HbA 1c . In contrast, the expression of IL1R2, PDGFRA, SFRP4, and PTGES was positively correlated with reduced insulin secretion and higher HbA 1c levels . We also tested whether 3,122 SNPs within a region of ± 50 kb of the 18 differentially expressed genes would show association with T2D in the DIAGRAM+ database at p < 0.001. As seen for the T2DNet, a SNP in the LRFN2 gene (rs892367) showed nominal association with T2D (p = 0.0001).
Genes Associated with T2D Based upon Bioinformatic Ranking Finally, we included the 14 genes from the T2DNet core, 8 genes from the PPI network (Ins gene was excluded from ranking as it was not annotated in our Affymetrix chip), 18 genes showing differential expression between hyperglycemic and normoglycemic patients and 10 genes with top-ranked SNPs in the DIAGRAM database together with the 48 T2D seeder genes to make a final rank list of 98 putative T2D genes. We used five different criteria to rank the genes: (1) correlation of gene expression in human islets with insulin secretion, (2) correlation of gene expression in human islets with HbA 1c , (3) SNPs within a region of ± 50 kb of the gene associated with T2D in the DIAGRAM+ database (with the lowest p value), (4) differential expression in intact pancreatic islets from diabetic and nondiabetic donors, and (5) bioinformatic analysis of a published data set on differential expression in pancreatic b cells from diabetic and nondiabetic individuals (Marselli et al., 2010) . The genes Module 1 T2D genes from T2DNet
Module 2 T2D genes from T2DNet
Module 3 T2D genes rom T2DNet
Module 4 T2dDgenes from T2DNet
Other T2Dgenes from STRING interac n data Genes prioritized from network topology were given a rank from 1 to 98 according to the above-listed criteria (Table S7) ; genes with the lowest ranking sum will be the top-ranked genes. Out of the top 20 ranked genes, 7 genes were among the genes showing differential expression in islets from hyperglycemic and/normoglycemic donors (RASGRP1, CHL1, PDGFRA, LRFN2, FAM105A, GLP1R, and GPR120), 5 genes were derived from the T2DNet (PPM1K, ELAVL4, KLHDC5, CLCN4, and MAPRE3), 5 genes from the 48 T2D seeder genes (JAZF1, SLC2A2, G6PC2, KCNJ11, and SLC30A8), 3 genes from the top 10 in the DIAGRAM data set (RASGRF1, LRFN2, and PLCB4), and one gene from the PPI network (ABCC8) ( Table 1) . The gene encoding JAZF1 (zinc finger 1) was top ranked, followed by CHL1 (cell adhesion molecule with homology to L1CAM), LRFN2 (leucine-rich repeat and fibronectin type III domain containing 2) and RASGRP1 (RAS guanyl releasing protein 1). Interestingly, the top 20 genes explained 7% and 24% of the variance in insulin secretion and HbA 1c . Moreover, the mean centroid of these 20 genes differed strongly between hyperglycemic and normoglycemic donors (p = 0.005) and was positively correlated with insulin secretion (R = 0.45; p = 0.001) and negatively with HbA 1c levels (R = À0.50; p = 0.0001) ( Figures  5A and 5B ).
GPR120 Knockdown Increased Apoptosis in Human Islets
GPR120 is an omega-3 fatty acid receptor and has been shown to mediate GLP-1 secretion (Hirasawa et al., 2005) . Culturing of human islets with eicosapentaenoic acid (EPA), a GPR120 activating agent, prevented palmitate and linoleic acid-induced apoptosis and increased cell viability, but did not appreciably influence glucose-induced apoptosis. Knockdown of GPR120 in human islets diminished the ability of EPA to prevent apoptosis induced by palmitate or linoleic acid by 50% ( Figures 5C and 5D ). However, we did not observe a significant effect of EPA on insulin secretion during the 1 hr incubation period.
Functional Studies in Clonal Rat b Cells
To obtain some insight into whether any of the other top-ranked genes would influence glucose-stimulated insulin secretion, we used RNA interference to silence expression of JAZF1, CHL1, LRNF2, RASGRP1, RASGRF1, KLHDC5, PLCB4, ELAVL4, IL1R2, PDGFRA, and the PPM1K genes in INS-1 cells (831/13). Silencing of CHL1, LRFN2, and PPM1K resulted in reduced glucose-stimulated insulin secretion, whereas RASGRP1 silencing resulted in increased insulin secretion (Figures 6 and S6) . No Genes were ranked based on their expression correlation with insulin secretion, HbA 1c , SNP associated with T2D in DIAGRAM+ database, and differential expression in donors with T2D versus healthy (in intact islets and pancreatic b cells). The genes were ranked for each parameter, and the sum score is denoted (low sum means highly ranked genes). a Genes derived from the 48 T2D genes. b Genes derived from the differential expression in islets from hyper/normoglycemic donors. c Genes derived from the T2DNet. d Genes derived from the top ten genes in the DIAGRAM data set. e Genes derived from the PPI.
effect on secretion was seen after siRNA silencing of JAZF1, RASGRF1, PLCB4, KLHDC5, ELAVL4, IL1R2, and PDGFRA. In an independent study, we observed that overexpression of SFRP4 ( Figure 4A ) was associated with increased expression of inflammatory markers and impaired insulin secretion.
DISCUSSION
The current paper presents a comprehensive map linking genetic variation with gene expression and function in a large number of well-characterized human islets. The analyses provide a list of potential T2D genes based upon coexpression with known T2D genes, differential expression in islets from T2D and nondiabetic islet donors, and correlation with metabolic phenotypes.
The PPI network extended the analysis of transcripts to predicted proteins and protein pathways. Most of the proteins identified as having strong connection to known T2D-associated genes encode key genes in pancreatic development (PDX1, NEUROD1, FOXA2, and PAX6) in addition to insulin and glucagon. The genes involved in pancreatic development have also been suggested to cause monogenic forms of diabetes (MODY) (Malecki et al., 1999; Stoffers et al., 1997) .
To summarize the findings from the different subanalyses, we ranked the identified genes based upon five different criteria. The ten top-ranked genes explained 22% of the variance in HbA 1c , which is higher than 2.4%, explained by ten SNPs in a GWAS of HbA 1c concentrations in > 46,000 Europeans (Soranzo et al., 2010) . HbA 1c provides a robust estimate of glycemic excursions during the preceding weeks and has been suggested (C-E) Human islets transfected with scrambled (Scr) or shRNA for GPR120 (KD) were treated with 5.5 mM glucose, 100 mM eicosapentaenoic acid (EPA), 250 mM palmitate, or 250 mM linoleic acid for 1 hr prior to measurement of cell apoptosis by MTS. Treatment of human islets with EPA GPR120 prevented palmitate and linoleic acid-induced apoptosis and increased cell viability but had only a modest effect on insulin secretion (C). Knockdown of GPR120 in human islets resulted in diminished ability of EPA to prevent apoptosis induced by palmitate or linoleic acid by 50%. No effect was observed on insulin secretion (D). The knockdown of GPR120 was estimated to be 65% as measured by RT-PCR (E). Bars represent mean ± standard deviation (SD).
as a diagnostic test for diabetes (http://www.who.int/diabetes/ publications/report-hba1c_2011). HbA 1c also has the advantage that it is unlikely to be influenced by the ultimate treatment the donors have received.
We acknowledge that the use of HbA 1c to differentiate between expressions in islets from hyperglycemic and normoglycemic individuals may infer a circular element to the ranking. However, excluding the 18 genes derived from this analysis for the ranking did not alter the results markedly; the top 20 genes still explained 22% of the variance in HbA 1c . The cutoff for ranking is of course arbitrary, but increasing the number of top-ranked genes from ten to 20 or 40 did not significantly change the proportion of the variance of HbA 1c explained. It remains to be shown whether this is an indication that the first ten top-ranked genes already picked key pathways contributing to abnormal glucose tolerance and that most additional genes from the ranking list came from the same pathways, thereby adding little to the explanation of the variance in HbA 1c .
Importantly, the correlation between gene expression in human islets and HbA 1c and insulin secretion cannot be interpreted as evidence of causality, i.e., the changes in gene expression precede the changes observed in insulin secretion and HbA 1c . It could also be the other way around, that elevated glucose induces changes in gene expression. There is some further information to clarify these relationships. Of the 50 topranked genes, 84% (6% after Bonferroni correction) and 34.1% of the 48 T2D seeder genes (2%) correlated with HbA 1c compared with 12% (0.7%) of all 20,000 genes on the array. The corresponding figures for genes correlating with both (B-L) individual siRNA experiments for the above-listed genes show insulin secretion in response to 2.8 mM and 16.7 mM glucose 72 hr after siRNA transfection as measured during 1 hr static incubation. Secretion was expressed as fold increase (insulin secreted at 16.7 mM/insulin secreted at 2.8 mM glucose) and normalized for protein content (ng/mg/hr). Data are shown from three independent experiments for each siRNA. Bars represent mean ± SEM. * < 0.05, ** < 0.01.
HbA 1c and insulin secretion were 54% for the top-ranked genes, 12% for the T2D seeder genes, and 3.4% for all genes on the array. From these data we can conclude that more of the 48 seeder genes and particularly the top-ranked 50 genes are associated with measures of glucose homeostasis, the direction of which cannot be inferred from the data. To gain insight into the direction of the effect, we silenced expression of 12 genes, JAZF1, CHL1, LRNF2, RASGRP1, RASGRF1, KLHDC5, PLCB4, ELAVL4, IL1R2, PDGFRA, and PPM1K, using siRNA in INS-1 cells, as well as of GPR120 using shRNA in human islets. These results obtained in a clonal rat insulinoma cell line suggest that disruption of CHL1, LRFN2, RASGRP1, and PPM1K results in altered insulin secretion. The CHL1 gene encodes for a neural adhesion molecule, which has been ascribed a role in regulation of GABA and activation of the MAP/ERK pathway (Huang et al., 2011) . The gene has been shown to be differentially expressed in pancreas from patients with pancreatic cancer (Senchenko et al., 2011) . Expression of CHL1 in human islets was strongly related to HbA 1c and insulin secretion ( Figure 4C ) and decreased in islets and b cells from patients with T2D (Marselli et al., 2010) ( Figure 4A ). Additionally, expression of CHL1 was significantly correlated with the insulin content (R = 0.30; p = 0.02). It has been suggested that adhesion molecules might be involved in the development of islet structure and determine distribution of b, a, and d cells in pancreatic islets (Cirulli et al., 1994) .
LRFN2 (leucine-rich repeat and fibronectin type III) encodes a protein known to promote growth of hippocampal neurons and regulate cell surface expression of NMDA receptor subunits. High expression of LRFN2 in islets was associated with better insulin secretion and lower HbA 1c ( Figure 4E ).
The PPM1K gene encodes for the mitochondrial branchedchain a-ketoacid dehydrogenase phosphatase, which catalyzes oxidative decarboxylation of branched-chain a-ketoacids from leucine, isoleucine, and valine (Wynn et al., 2012) . Given the central role ascribed to branched-chain amino acids in the pathogenesis of T2D and insulin resistance (Newgard et al., 2009; Wang et al., 2011) and a recent finding demonstrating that SNPs in the PPM1K gene showed strong association with the Fisher ratio (ratio of branched-chain amino acids to aromatic amino acids) (Kettunen et al., 2012) , it is interesting to speculate that similar mechanisms as described in muscle might also be operative in islets.
Although we did not observe any effect of silencing of PDGFRA (platelet-derived growth factor receptor A) on insulin secretion, there is prior evidence that disruption of PDGFRA impairs b cell regeneration in streptozotocin-treated mice and that PDGFR levels decline with age in parallel with a decline in b cell replication (Chen et al., 2011) . This could suggest that a decrease in expression of PDGFRA influences insulin secretion only under diabetic conditions.
In contrast to expectations from findings in diabetic islets showing decreased expression of RASGRP1, silencing of RASGRP1 resulted in markedly increased insulin secretion in INS-1 cells. In keeping with the findings in islets, RASGRP1 (RAS guanyl releasing protein 1) showed marked downregulation in b cells from patients with T2D (Marselli et al., 2010) . The encoded protein activates the MAP/ERK pathway and enhances endocytosis of the sodium-chloride cotransporter (Ko et al., 2010) . Variation in the gene has been associated with T1D (Qu et al., 2009) . These data thereby highlight the problem of generalizing data from short-term perturbations to the situation of chronic hyperglycemia characteristic of T2D.
We did not observe any effect of silencing of JAZF1, RASGRF1, KLHDC5, ELAVL4, PLCB4, and IL1R2 on glucosestimulated insulin secretion. It therefore still remains to be shown whether this reflects a failure of the experimental situation, that the observed differences in expression of these genes could be a consequence of chronic hyperglycemia, or that effect on insulin secretion also requires perturbation of coexpressed networks. Of these genes, ELAVL4 is particularly interesting, not only because it is a putative target of miRNA-375, a key miRNA involved in regulation of b cell mass and function (Poy et al., 2004) , but also since ELAVL4 was shown to reside in a region of open chromatin as assessed by FAIRE enrichment (Gaulton et al., 2010) or H3K4me3 peaks (Stitzel et al., 2010) in human islets.
SFRP4 (secreted frizzled-related protein 4) contains cysteinerich domains homologous to the Wnt binding sites of Frizzled proteins. High expression in islets was associated with impaired insulin secretion and high HbA 1c levels ( Figure 4A ). This was further supported by independent results from our laboratory showing that recombinant SFRP4 inhibited in vitro insulin secretion by 30% and b cell exocytosis by 50% in human islets.
GPR120 encodes for a G protein-coupled receptor known to stimulate secretion of GLP-1. It is stimulated by unsaturated fatty acids, particularly omega-3 fatty acids (Hirasawa et al., 2005) . Here we noted that its expression in human islets was positively correlated with insulin secretion and insulin content (R = 0.25; p = 0.04) and with lower HbA 1c ( Figure 4B ). Second, activation of GPR120 with EPA prevented lipid-induced apoptosis and increased cell viability. However, this effect was reduced by 50% in human islets after disruption of GPR120. Although we could not observe a significant effect on insulin secretion during the short incubation period, the data suggest that GPR120 can protect pancreatic islets from lipotoxicity ( Figures 5C and 5D ).
On the other hand, several genes from loci associated with T2D gathered at the bottom of the list, including KCNQ1, CDKAL1, ADRA2A, CAMK1D, and GIPR, etc. This may suggest that the effect of these variants on risk of T2D affects a specific splice isoform pattern rather than total gene expression. Another explanation could be that expression of most of these genes in islets was relatively low. This type of reasoning is relevant to TCF7L2, for which there is accumulating evidence that the risk genotype in TCF7L2 influences splicing pattern rather than absolute levels of expression (Le Bacquer et al., 2011; Osmark et al., 2009) .
There are some limitations with the study we need to take into account. One caveat when generalizing from SNPs to genes is that SNPs usually are associated with a chromosomal locus rather than a gene. Although we here focused on the nearest gene to the SNP, we cannot exclude the possibility that some of the other nearby genes are the true targets of the SNP. We therefore hoped that the analysis of cis eQTLs would help in identifying causal genes, but only five cis eQTLs were observed using these stringent criteria, and these SNPs were from genes/ loci (CAMK1D, HHEX, MADD, KCNQ1, and GCKR) with fairly well-described functions in metabolism. None of the cis eQTLs showed differential expression in islets from normoglycemic and hyperglycemic donors.
Another caveat could be purity of human cadaver islets and differences in contribution of exocrine and endocrine tissue or different contribution of a and b cells between normoglycemic and hyperglycemic donors. Although there was a small decrease in purity as measured by dithizone staining in islets from T2D versus nondiabetic islets (10%, p = 0.15), adjusting gene expression for differences in purity did not significantly change the results, nor were they influenced by adjustment for DNA content. Also, the contribution of exocrine and endocrine tissue did not significantly differ between diabetic and nondiabetic islets (see Experimental Procedures). In analogy with the issue of whether changes in gene expression are the cause or consequence of increased HbA 1c , we cannot from the current crosssectional data conclude whether changes in gene expression are the cause or a consequence of a reduction in b cell mass. A recent paper on patients undergoing pancreatic surgery showed that 65% of b cell mass was lost at onset of diabetes, but the paper did not provide any information on gene expression (Meier et al., 2012) . Notably, we did not attempt to include two groups of human islets, i.e., islets from T2D and nondiabetic donors; rather, the HbA 1c values indicate that the donors represent the whole spectrum from normal to impaired and diabetic glucose tolerance. However, only large enough numbers can outweigh the problems of heterogeneity and purity.
Taken together, these results combining SNP information and islet gene expression with relevant in vitro and in vivo measurements in humans present a map of potential genes involved in T2D pathogenesis. Thereby, systems genetics may help to link the plethora of T2D-associated SNPs and loci to pathways of relevance for islet function and pathogenesis of T2D. Functional studies will be required to pinpoint the mechanisms by which they impair islet function and increase risk of T2D.
EXPERIMENTAL PROCEDURES Human Pancreatic Islets
Islets from cadaver donors (54 nondiabetic and 9 diabetic) were provided by the Nordic Islet Transplantation Programme (http://www.nordicislets.org), coordinated by Olle Korsgren, Uppsala University. Islets were obtained from 54 nondiabetic donors (25 females, 29 males, age 59 ± 9, BMI 25.9 ± 3.5, HbA 1c 5.5 ± 1.1) and 9 T2D donors (4 females, 5 males, age 57 ± 4, BMI 28.5 ± 4.5, HbA 1c 7.2 ± 1.1). Purity of islets was assessed by dithizone staining and was 57% ± 19% in the T2D and 67% ± 17% in the nondiabetic islets (p = 0.15). We also measured the DNA content in islets from diabetic and nondiabetic donors; no difference was observed between the groups (2.5 ng/islet versus 2.2 ng/islet; p = 0.6). In addition, we also tried to obtain an estimate of the contribution of exocrine and endocrine tissue by measuring expression of pancreatic lipase, alpha 2 amylase and chymotrypsin 2 as markers of exocrine and somatostatin and glucagon as markers of endocrine tissue (probes for insulin were not on the Affy chip). Using this approach, the contribution of endocrine tissue did not differ between nondiabetic and T2D donors (72% versus 68%, p = 0.29). A modest, insignificant decrease in insulin content in islets from hyperglycemic versus normoglycemic donors was observed (8.8 ± 3.2 ng/islet versus 10.6 ± 3.2 ng/islet; p = 0.4). All procedures were approved by the ethics committees at Uppsala and Lund Universities.
Microarray Gene Expression in Human Pancreatic Islets
The microarrays were performed using GeneChip Human Gene 1.0 ST whole transcript according to Affymetrix standard protocol. The microarrays were performed using GeneChip Human Gene 1.0 ST whole transcript according to Affymetrix standard protocol. All data are MIAME compliant, and the raw data have been deposited in a MIAME database (GEO, accession number: GSE38642). Microarray procedure is described in detail in Supplemental Experimental Procedures.
Glucose-Stimulated Insulin Secretion
Insulin secretion analysis is described in detail in the Supplemental Experimental Procedures.
Genotyping GWAS was performed using Genome-Wide Human SNP array (SNP 6.0), and the 47 T2D-associated SNPs were genotyped by allelic discrimination with TaqMan assay on the ABI 7900 platform. More details are given in Supplemental Experimental Procedures.
Coexpression Analysis
Genes showing correlation of Spearman rho (r s ) > 0.8 or < À0.8 where considered coexpressed. All coexpression data passed Bonferroni correction (p = 4.73 3 10 À8 ). For more details see Supplemental Experimental
Procedures.
Molecular Interaction Networks
Genes in the connection groups were analyzed in the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) database, version 8, for proteinprotein interactions (Szklarczyk et al., 2011) . The EAGLE clustering algorithm was used for detecting the subnetworks from the protein-protein (PPI) interaction network. The EAGLE algorithm was used to identify the network modules with CliqueSize threshold = 3 and OutputThreshold = 2. Cytoscape software (version 2.6) was used to visualize and analyze molecular and interaction networks (http://www.code.google.com/p/clusterviz-cytoscape/). Topological network properties were calculated using Network Analyzer in Cytoscape. Nodes in the network were classified according to the degree of connectivity based on the Lu et al. scheme (Lu et al., 2007) . Superhubs were defined as nodes having connectivity greater 100, hubs as nodes with > 20 and < 100, peripheral-A as nodes with connectivity > 2 and < 20, and peripheral-B as those with only one interacting partner. Gene ontology (GO) enrichment of the network was carried out using the Cytoscape-BINGO program to detect significantly overrepresented GO biological processes (Maere et al., 2005) . BINGO applies Benjamini and Hochberg multiple-test corrections at a significance level of p < 0.05.
cis and trans eQTL Detection To identify cis and trans eQTLs, we assessed significance of expression changes in the data set of 20,000 genes by applying a linear model with the assumption of additive effect (corrected for age and sex). cis eQTLs were defined as significant associations between the 47 T2D-associated SNPs and expression of genes within 1 Mb distance, whereas trans were considered associations with expression of any other gene outside this interval. A permutation significance threshold (p < 0.001) for cis eQTLs was defined based on 1,000 permutations of the sample expression vectors. The p value threshold (p < 0.00019) for the trans eQTLs was defined by looking at the distribution of best p values from 1,500 random SNP-gene test pairs, then selecting the top 5% most significant p value (p < 0.00019).
Differences in Expression of Genes between Patients with and without T2D
Omics Explorer, Version 2.0 Beta (Qlucore AB, Lund, Sweden, http://www. qlucore.se) was used to identify any gene on the chip showing differential expression between patients with and without T2D and donors with HbA 1c < 6% and > 6%). A nominal p value of < 0.001 was used to identify differentially expressed genes. The mean centroid represents the normalized gene expression levels of all genes from all individuals in the analysis to a mean of 0 and a variance of 1 (Mootha et al., 2003) .
DIAGRAM Database DIAGRAM database is described in details in Supplemental Experimental Procedures.
Statistical Analysis
Differences in expression of 48 putative known T2D genes in diabetic versus nondiabetic or normoglycemic versus hyperglycemic donors were tested using nonparametric Mann-Whitney test (two-tailed). Nonparametric Spearman's test was used for testing correlation between gene expression, HbA 1c , and/or insulin secretion. Data are presented as means ± SEM (standard error of the mean) or ± SD (standard deviation). Expression variation of the top 20 genes in HbA 1c and insulin secretion were analyzed using linear regression test. All statistical tests were performed using statistical package for the social sciences (SPSS) version 19.0 software (SPSS, Chicago, IL, USA) and R package.
ACCESSION NUMBERS
The raw data have been deposited in a MIAME database under accession number GSE38642 
